GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ocugen Inc (FRA:2H51) » Definitions » Float Percentage Of Total Shares Outstanding

Ocugen (FRA:2H51) Float Percentage Of Total Shares Outstanding : 98.11% (As of Jun. 08, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Ocugen Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Ocugen's float shares is 252.49 Mil. Ocugen's total shares outstanding is 257.35 Mil. Ocugen's float percentage of total shares outstanding is 98.11%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Ocugen's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Ocugen's Institutional Ownership is 9.61%.

Ocugen Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Ocugen's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=252.49/257.35
=98.11%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ocugen (FRA:2H51) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ocugen Inc (FRA:2H51) » Definitions » Float Percentage Of Total Shares Outstanding
Comparable Companies
SGMO BDTX NYMXF KPTI ABEO ALDX RLMD HOWL MIRO GMDA OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
OCGN:USA OCGN:Mexico
Address
11 Great Valley Parkway, Malvern, PA, USA, 19355
Website
https://www.ocugen.com
Ocugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. The breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug one to many and novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema and diabetic retinopathy. The company is co-developing Bharat Biotech's COVAXIN vaccine candidate for COVID-19 in the U.S. and Canadian markets.

Ocugen (FRA:2H51) Headlines

No Headlines